Multicenter evaluation of Verigene Enteric Pathogens Nucleic Acid Test for detection of gastrointestinal pathogens.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
04 02 2021
Historique:
received: 21 08 2020
accepted: 20 01 2021
entrez: 5 2 2021
pubmed: 6 2 2021
medline: 11 11 2021
Statut: epublish

Résumé

We investigated the efficiency of the Verigene Enteric Pathogens Nucleic Acid Test (Verigene EP test), which is an automated microarray-based assay system that enables rapid and simultaneous genetic detection of gastrointestinal pathogens and toxins, including those in the Campylobacter Group, Salmonella species, Shigella species, the Vibrio Group, Yersinia enterocolitica, Shiga toxin 1 and 2, norovirus GI/GII, and rotavirus A. Three clinical laboratories evaluated the Verigene EP test, using 268 stool samples for bacterial and toxin genes and 167 samples for viral genes. Culture-based reference methods were used for the detection of bacteria and toxins, while a different molecular assay was used for viral detection. The overall concordance rate between the Verigene EP test and the reference methods for the 1940 assays was 99.0%. The overall sensitivity and specificity of the Verigene EP test were 97.0% and 99.3%, respectively. Of the 19 samples with discordant results, 13 samples were false positives and six were false negatives. The Verigene EP test simultaneously detected two targets in 11 samples; overall, the test demonstrated high efficiency in detecting crucial diarrheagenic pathogens, indicating its suitability for clinical practice.

Identifiants

pubmed: 33542335
doi: 10.1038/s41598-021-82490-z
pii: 10.1038/s41598-021-82490-z
pmc: PMC7862589
doi:

Substances chimiques

Bacterial Toxins 0
Shiga Toxin 1 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3033

Références

J Clin Microbiol. 2014 Oct;52(10):3667-73
pubmed: 25100818
J Infect. 2015 May;70(5):504-11
pubmed: 25449904
J Clin Microbiol. 2015 Mar;53(3):915-25
pubmed: 25588652
Diagn Microbiol Infect Dis. 2016 Dec;86(4):336-339
pubmed: 27720206
Lett Appl Microbiol. 1999 Jan;28(1):52-6
pubmed: 10030032
J Clin Microbiol. 2003 Apr;41(4):1548-57
pubmed: 12682144
Lab Med. 2019 Oct 10;50(4):390-395
pubmed: 31065712
J Clin Microbiol. 2013 Sep;51(9):3018-24
pubmed: 23850948
Biomol Detect Quantif. 2014 Aug 14;1(1):3-7
pubmed: 27920992
Microbiol Spectr. 2014 Aug;2(4):EHEC-0024-2013
pubmed: 25530917
Am J Gastroenterol. 2016 May;111(5):602-22
pubmed: 27068718
J Infect Chemother. 2017 Oct;23(10):674-677
pubmed: 28751156
Int J Infect Dis. 2015 May;34:33-7
pubmed: 25749649
J Clin Microbiol. 2010 Nov;48(11):4140-6
pubmed: 20861334
N Engl J Med. 2004 Jan 1;350(1):38-47
pubmed: 14702426
Eur J Clin Microbiol Infect Dis. 2019 Jun;38(6):1087-1093
pubmed: 30783889

Auteurs

Kosuke Kosai (K)

Department of Laboratory Medicine, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, Nagasaki, 852-8501, Japan. k-kosai@nagasaki-u.ac.jp.

Hiromichi Suzuki (H)

Division of Infectious Diseases, Department of Medicine, Tsukuba Medical Center Hospital, Ibaraki, Japan.

Kiyoko Tamai (K)

Miroku Medical Laboratory Inc., Nagano, Japan.

Yuya Okada (Y)

Department of Laboratory Medicine, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, Nagasaki, 852-8501, Japan.

Norihiko Akamatsu (N)

Department of Laboratory Medicine, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, Nagasaki, 852-8501, Japan.

Atsuo Ueda (A)

Department of Clinical Laboratory, Tsukuba Medical Center Hospital, Ibaraki, Japan.

Shigeyuki Notake (S)

Department of Clinical Laboratory, Tsukuba Medical Center Hospital, Ibaraki, Japan.

Yuji Yaguchi (Y)

Miroku Medical Laboratory Inc., Nagano, Japan.

Katsunori Yanagihara (K)

Department of Laboratory Medicine, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, Nagasaki, 852-8501, Japan.
Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH